计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Baricitinib (INCB028050), 酪氨酸蛋白激酶 JAK2 抑制剂
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Baricitinib (LY3009104, INCB028050)是一种选择性的JAK1和JAK2抑制剂，IC50分别为5.9 nM和5.7 nM，比作用于JAK3和Tyk2选择性高70和10倍左右，对c-Met和Chk2没有抑制作用。A selective inhibitor of JAK1 and JAK2.
Information
Baricitinib (LY3009104, INCB028050) is a selectiveJAK1andJAK2inhibitor withIC50of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the pass
In vitro
Baricitinib inhibits IL-6–stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively, in PBMCs. Baricitinib also inhibits pSTAT3 stimulated by IL-23 with IC50 od 20 nM in isolated naive T-cells.
In vivo
Baricitinib inhibits IL-6–stimulated phosphorylation of STAT3 in whole blood with an IC50 of 128 nM. Baricitinib (10 mg/kg p.o.) is expected to inhibit JAK1/2 signaling (by ≥50%) in rats for about 8 hours. Baricitinib (10 mg/mL, p.o.) inhibits disease scores in dose-dependent manner in rats with established disease in the adjuvant arthritis model. Baricitinib treatment, compared with vehicle, inhibits the increase in hind paw volumes during the 2 weeks of treatment by 50% at a dose of 1 mg/kg and >95% at doses of 3 mg/kg or 10 mg/kg. Baricitinib treatment, compared with vehicle, also inhibits composite score of immune infiltrate, edema, and periarticular tissue appearance by 27% at a dose of 1 mg/kg, 64% at doses of 3 mg/kg and 82% at doses of 10 mg/kg in rats with established disease in the adjuvant arthritis model. Baricitinib reduces bone resorption by 15%, 61%, and 67% with increasing dose level (1, 3, and 10 mg/kg) in rats with established disease in the adjuvant arthritis model. Baricitinib (10 mg/kg, daily for 2 wk, p.o.) results in radiographic improvements with restoration of the normal architecture and appearance to the ankle and tarsals in rats with established disease in the adjuvant arthritis model. Baricitinib reduces levels of pSTAT3 in a dose- and time-dependent manner in the peripheral blood of rAIA animals. Baricitinib (10 mg/mL, p.o.) improves a composite score of joint damage by 47% in the murine CIA model. Baricitinib (10 mg/kg) reduces pannus (74%) and bone damage (78%) and improves cartilage damage (43%) and signs of inflammation (33%), resulting in a 53% improvement in an aggregate score of disease in the collagen Ab-induced arthritis (CAIA) murine model. Baricitinib (10 mg/kg) inhibits the delayed-type hypersensitivity response by 48% in both the CIA and CAIA models. Baricitinib is efficacious in active rheumatoid arthritis patients refractory to disease modifying drugs and biologics. Baricitinib preferentially inhibits JAK1 and JAK2, with 10-fold selectivity over Tyk2 and 100-fold over JAK3. The observed effects of GLPG-0634 on the ACR20, albeit in a smaller study, appear to be at least as good as that seen with tofacitinib and superior to that of baricitinib, since baricitinib only moderately affect the ACR20 values in Phase IIa clinical studies. Baricitinib has the dose-limiting side-effect of inducing anaemia which has been attributed to its effects on JAK2 but has clearly shown efficacy.
Cell Data
cell lines：
Concentrations：
Incubation Time：
Powder Purity:≥99%
规格
别名
巴瑞替尼 (INCB028050)
英文别名
LY3009104 | 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
规格或纯度
Moligand™, 10mM in DMSO
英文名称
Baricitinib (INCB028050)
生化机理
Baricitinib（LY3009104，INCB028050）是一种选择性 JAK1 和 JAK2 抑制剂，在无细胞实验中的 IC50 为 5.9 nM 和 5.7 nM，对 JAK3 和 Tyk2 的选择性分别为 ~70 倍和 ~10 倍，对 c-Met 和 Chk2 无抑制作用。Baricitinib 可减少或阻断病毒进入靶细胞，被用于 COVID-19 的治疗研究。第三阶段
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
酪氨酸蛋白激酶 JAK2 抑制剂
名称和识别符
EC号
691-421-4
分子类型
小分子
Isomeric SMILES
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
分子量
371.42
Reaxy-Rn
19442770
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19442770&ln=
技术文档
高级数据
产品属性
| ALogP | -0.5 |
|---|
关联靶点（人）
TYK2
Tclin
非受体酪氨酸蛋白激酶 TYK2(Non-receptor tyrosine-protein kinase TYK2)
(2 活性数据)
JAK3
Tclin
酪氨酸蛋白激酶JAK3(Tyrosine-protein kinase JAK3)
(2 活性数据)
SEPT9
Tchem
塞普汀-9(Septin-9)
(1 活性数据)
JAK1
Tclin
酪氨酸蛋白激酶JAK1(Tyrosine-protein kinase JAK1)
(11 活性数据)
BMP2K
Tchem
BMP-2诱导蛋白激酶(BMP-2-inducible protein kinase)
(1 活性数据)
Tchem
未表征蛋白 FLJ45252(Uncharacterized protein FLJ45252)
(1 活性数据)
AAK1
Tchem
AP2 相关蛋白激酶 1(AP2-associated protein kinase 1)
(1 活性数据)
JAK2
Tclin
酪氨酸蛋白激酶JAK2(Tyrosine-protein kinase JAK2)
(12 活性数据)
化学和物理性质
溶解性
Solubility (25°C) In vitro DMSO: 6 mg/mL (26.64 mM); Water: Insoluble; Ethanol: Insoluble;
安全和危险性（GHS）
信号词
Danger
危险声明
H373: 通过长时间或反复暴露对器官造成损害
H411: 对水生生物有毒并具有长期持续影响
H302: 吞食有害
H360: 可能损害生育力或未出生的孩子
预防措施声明
P273: 避免释放到环境中。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P405: 密闭存放
P501: 将内容物/容器处理到。。。
P264: 处理后要彻底洗手。
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。
P270: 使用本产品时，请勿进食、饮水或吸烟。
P391: 收集溢出物
P330: 漱口
P203: 使用前，获取、阅读并遵守所有安全说明。
P301+P317: 如果被吞咽：请寻求医疗帮助。
P318: 如果暴露或担心，请就医。
P319: 如果你感到不适，请寻求医疗帮助。
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）